The Food and Drug Administration on Nov. 9 approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa, or FXIa, inhibitor cleared for use with antiplatelet therapy to reduce the risk of stroke in certain adults. The indication covers people following a recent mild-to-moderate non-cardioembolic ischemic stroke, meaning a stroke caused by a clot that did not originate in the heart, or a high-risk transient ischemic attack, often called a mini-stroke.
"Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke," said Hylton V. Joffe, M.D., MMSc, director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA's Center for Drug Evaluation and Research. "Today's approval represents a meaningful advance for patients and health care providers seeking a new option for secondary stroke prevention."
Effectiveness was shown in OCEANIC-STROKE, a multicenter, randomized, double-blind, placebo-controlled phase 3 study that enrolled 12,327 adults. Participants had a recent non-cardioembolic ischemic stroke, with an NIH Stroke Scale score of 15 or less, or a high-risk TIA, and were randomly assigned to Sunharbo or placebo within 72 hours of symptom onset. Both groups also received antiplatelet therapy. Sunharbo 50 mg once daily significantly reduced the risk of ischemic stroke by 26% compared with placebo over a median treatment of 14.2 months, the FDA said.
The overall rate of major bleeding was similar between the Sunharbo and placebo groups, but it was increased with Sunharbo in patients older than 75 years and during the first 90 days of treatment. Gastrointestinal bleeding occurred more commonly with Sunharbo than with placebo. The most frequently reported adverse reaction, occurring in 3% or more of Sunharbo-treated patients, was diarrhea.
The agency listed several limits that are part of the approval, not optional fine print. Concomitant use with medicines that are combined P-gp and strong CYP3A4 inducers, such as carbamazepine, is not recommended because those medicines may decrease Sunharbo's effectiveness. Sunharbo is not recommended in patients with moderate or severe hepatic impairment. It should be withheld at least 24 hours before elective surgery or invasive procedures and for at least 24 hours after thrombolysis for acute ischemic stroke.
Sunharbo is not approved for stroke prevention in patients with atrial fibrillation, the FDA said. That distinction matters for readers who may hear "stroke prevention pill" and assume it applies to every stroke risk, including clots tied to an irregular heartbeat. The Nov. 9 decision does not cover that use.
The FDA granted Sunharbo Fast Track and Priority Review designations. The approval was granted to Bayer HealthCare Pharmaceuticals Inc., of Whippany, N.J. The agency's announcement is a first-in-class approval for this mechanism in the described post-stroke and high-risk TIA setting. It is not a finding that the drug replaces antiplatelet therapy, which patients in the trial also received, and it is not a report of a Bay Area-specific shortage or local formulary change.
